ResMed Inc. (RMD): Price and Financial Metrics
ResMed Inc. (RMD)
Today's Latest Price: $179.41 USD
Updated Oct 19 6:30pm
Add RMD to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 142 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
RMD Stock Summary
- Resmed Inc's market capitalization of $26,196,589,237 is ahead of 92.12% of US-listed equities.
- The price/operating cash flow metric for Resmed Inc is higher than 87.8% of stocks in our set with a positive cash flow.
- In terms of volatility of its share price, RMD is more volatile than just 6.98% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Resmed Inc are A, HOLX, CERN, LOGI, and VAR.
- RMD's SEC filings can be seen here. And to visit Resmed Inc's official web site, go to www.resmed.com.
RMD Stock Price Chart Interactive Chart >
RMD Price/Volume Stats
| Current price | $179.41 | 52-week high | $208.99 |
| Prev. close | $180.79 | 52-week low | $108.85 |
| Day low | $178.84 | Volume | 425,619 |
| Day high | $183.07 | Avg. volume | 680,762 |
| 50-day MA | $175.39 | Dividend yield | 0.86% |
| 200-day MA | $169.79 | Market Cap | 26.00B |
ResMed Inc. (RMD) Company Bio
ResMed Inc. develops, manufactures, distributes, and markets medical equipment for the diagnosis, treatment, and management of respiratory disorders with a focus on sleep-disordered breathing. The company was founded in 1989 and is based in San Diego, California.
RMD Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $179.41 | $74.96 | -59% |
Below please find a table outlining a discounted cash flow forecast for RMD, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Resmed Inc ranked in the 27th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Resmed Inc ended up being:
- Interest coverage, a measure of earnings relative to interest payments, is 19.16 -- which is good for besting 84.83% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
- The business' balance sheet suggests that 5% of the company's capital is sourced from debt; this is greater than only 14.56% of the free cash flow producing stocks we're observing.
- RMD's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 44.16% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -59% |
| 1% | -59% |
| 2% | -59% |
| 3% | -58% |
| 4% | -58% |
| 5% | -57% |
IONS, XRAY, JNJ, PKI, and ILMN can be thought of as valuation peers to RMD, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...